UBS Group AG - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$62,506
-27.4%
52,971
-13.2%
0.00%
Q2 2023$86,063
+1663.6%
61,037
+1776.3%
0.00%
Q1 2023$4,880
-60.3%
3,253
-69.0%
0.00%
Q4 2022$12,291
+1129.1%
10,506
+706.9%
0.00%
Q3 2022$1,000
-94.4%
1,302
-88.6%
0.00%
Q2 2022$18,000
+1700.0%
11,420
+1177.4%
0.00%
Q1 2022$1,000
-99.0%
894
-97.8%
0.00%
Q4 2021$97,000
-81.5%
39,932
-80.8%
0.00%
Q3 2021$523,000
+3923.1%
207,702
+4468.9%
0.00%
Q2 2021$13,000
-23.5%
4,546
-38.0%
0.00%
Q1 2021$17,000
-61.4%
7,337
-70.2%
0.00%
Q4 2020$44,000
+4300.0%
24,602
+2098.6%
0.00%
Q3 2020$1,0000.0%1,119
-17.5%
0.00%
Q2 2020$1,000
-98.3%
1,357
-98.1%
0.00%
Q1 2020$59,000
-57.6%
70,916
-54.5%
0.00%
Q4 2019$139,000
+69.5%
155,913
+86.6%
0.00%
Q3 2019$82,00083,5730.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders